Episode Summary
This episode examines the rapid commercialization of NAD⁺ injections and NAD-boosting supplements, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), in the absence of robust clinical evidence. Despite NAD⁺'s established role in cellular energy metabolism and DNA repair, consumer adoption has significantly outpaced outcomes-based research, creating a public health concern that requires strengthened regulatory oversight and evidence-based policy intervention.
Key Topics Discussed
- NAD⁺ biology and mechanistic findings: The coenzyme's role in cellular metabolism, DNA repair, and immune regulation, and how basic science discoveries have been translated into unproven consumer interventions
- Biomarker changes versus clinical outcomes: The critical gap between measurable biochemical changes and demonstrated clinical benefit in disease prevention or longevity
- Adverse effects and pharmacological risks: Documented safety concerns observed in human studies and long-term uncertainties, including cardiovascular and cancer-related risks
- Supplement quality and regulatory gaps: Product adulteration, manufacturing standards, and limitations in regulatory oversight of NAD-boosting supplements
- Health misinformation and market adoption: The role of unsubstantiated wellness claims in accelerating population exposure to unproven interventions
- Public health and healthcare system implications: Potential burden on healthcare systems and population-level risks from widespread use without clinical indication
Key Takeaways
- NAD⁺ interventions remain biologically active but clinically unproven for disease prevention, longevity, or therapeutic benefit
- The combination of uncertain benefit, measurable risk, and increasing population exposure presents a concerning risk profile requiring precautionary policy
- Strengthened pharmacovigilance and post-market surveillance are essential for monitoring long-term safety and adverse events
- Evidence-based communication is critical to counteract health misinformation and prevent inappropriate adoption of unproven interventions
- Regulatory frameworks must bridge the gap between biomarker-based claims and outcomes-based evidence for supplement and injection-based interventions
About This Episode
This policy-focused analysis addresses an emerging public health challenge relevant to clinical practice, health policy, and regulatory decision-making globally. The rapid market expansion of NAD⁺ interventions illustrates broader concerns about translating mechanistic science into consumer products without adequate safety and efficacy evaluation. For healthcare systems in Georgia and internationally, this episode emphasizes the importance of evidence-based clinical guidance, strengthened pharmacovigilance infrastructure, and proactive regulatory engagement to protect population health while maintaining scientific credibility in an era of rapidly commercialized wellness interventions.
In this episode of the GMJ Podcast — the official podcast of the Georgian Medical Journal — we present a policy-focused analysis examining the rapid rise of NAD⁺ injections and NAD-boosting supplements in the context of public health, clinical evidence, and regulatory oversight.
Nicotinamide adenine dinucleotide (NAD⁺) is a fundamental coenzyme involved in cellular energy metabolism, DNA repair, and immune regulation. However, its growing use in wellness markets through injections, infusions, and oral supplements such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has significantly outpaced evidence on clinical effectiveness and long-term safety.
The analysis explores how mechanistic scientific findings have been translated into large-scale consumer interventions without sufficient outcomes-based evidence.
The episode examines key public health concerns, including:
• The gap between biomarker changes and clinically meaningful outcomes
• Adverse effects and pharmacological activity observed in human studies
• Long-term safety uncertainties, including cardiovascular and cancer-related risks
• Product quality issues, including supplement adulteration and regulatory limitations
• The role of health misinformation in accelerating adoption
• Implications for healthcare systems, including potential downstream burden
The findings highlight that NAD⁺ interventions, while biologically active, remain unproven in terms of disease prevention, longevity, or clinical benefit. From a public health perspective, the combination of uncertain benefit, measurable risk, and increasing population exposure represents a concerning risk profile.
This episode emphasizes the importance of precautionary policy, strengthened pharmacovigilance, and evidence-based communication in addressing emerging health trends.
https://gmj.ge/index.php/pub/article/view/15
https://gmj.ge/index.php/pub/article/view/15/10
https://doi.org/10.5281/zenodo.19051458
Pkhakadze, G. (2026). NAD⁺ Injections and “NAD Boosters”: Public Health Risks, Adverse Effects, and Regulatory Implications in the Context of Rapid Consumer Adoption. The Georgian Medical Journal, 1(1), 35–43.
https://doi.org/10.5281/zenodo.19051458